Organ On Chip Definition

The organ-on-chip market consists of sales of organs-on-chips by entities (organizations, sole traders and partnerships) that manufacture organs-on-chips used for drug development, toxicity testing, and personalized medicine research. Organs-on-chips (OOCs) are small plastic devices with biocompatible microfluidic chambers containing multiple live human cells in a 3D culture that simulate key physiological functions of body organs. Organs-on-chips that mimic the organ level physiology of humans are a promising alternative to animal models. The design and development of an OOC is made possible by using the relevant novel techniques from cell biology, microfabrication, microfluidics, material science and nanotechnology. The specific chip design varies based on manufacturing techniques and the organ it simulates, although the basic structure usually remains the same.

The cold and cough preparations refer to the medications that are used to treat cold and cough. The drugs for the treatment of cold and cough act on the receptors to which the virus causing the infection gets attached, by antagonizing the action of the receptors and killing the viral infection, thereby reducing congestion by lysing the mucus and dilating the bronchioles constricted by the mucus deposition. The main types of drugs in cold and cough preparations are antihistamines, expectorants, bronchodilators, decongestants, antibiotics, and others. Antihistamines are drugs or other compounds that block the physiological effects of histamine and are used to treat allergies in particular. The different types include bronchodilators, anticholinergic, and pulmonary antihypertensives. The several dosage types include oral syrups, tablets or pills, nasal drops, lozenges, and others and are distributed through various channels such as hospital pharmacies, retail pharmacies, and drug stores. The cold and cough preparations market research report is one of a series of new reports from The Business Research Company that provides cold and cough preparations market statistics, including cold and cough preparations industry global market size, regional shares, competitors with a cold and cough preparations market share, detailed cold and cough preparations market segments, market trends and opportunities, and any further data you may need to thrive in the cold and cough preparations industry. This cold and cough preparations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cough and cold preparations market size will grow from $66.75 billion in 2022 to $70.37 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cough and cold preparations market size is expected to grow to $84.02 billion in 2027 at a CAGR of 4.5%. The rising incidence of allergies is expected to fuel the growth of the cough and cold preparations market in the forecast period. There are many respiratory allergies such as pollen, dust, mold, and pet allergies; these allergies are caused due to contaminated outdoor and indoor air. Cough and cold preparations are consumed for treating allergies, which cause cough and cause issues in the respiratory tract. For instance, according to the European Academy of Allergy and Clinical Immunology, a non-profit organization for European clinicians, researchers, and allied health professionals, by 2025, 1 in every 3 people in the European Union is expected to be affected by allergies. Thus, the increase in the incidence of respiratory allergies will bolster the demand for cough and cold preparations, positively affecting the growth of the market. Threat from substitute products such as generic and counterfeit drugs is significantly restraining the global cold and cough preparations market. Pharmaceutical companies invest a large sum of money in the drug development process. Once a drug candidate is developed and approved by the regulatory authorities, companies patent their inventions to protect their intellectual property. During the patency period, the company holding the patent holds exclusivity for manufacturing and distribution. Post expiration of patency, generic versions of the drugs is manufactured by other companies. The prices of the generics are very low in comparison to the original brand of the drug. According to an article by Alpha InvesCo., a new FDA-approved blockbuster drug that netted $100 million a year in profit during its patent protection duration could become one that earns only $1 million a year in profit overnight after losing its patent. Additionally, there is a major international problem with counterfeit drugs. The best of these counterfeits duplicates a real drug’s formula and sells it at a lower price, which hurts pharmaceutical companies' profits. Moreover, counterfeits made with low-grade materials can destroy the reputations of legitimate products, thus affecting the growth of the market. Advancements in technologies are driving the global pharmaceutical sector including cold and cough preparations. According to a global life sciences report by Deloitte, the adoption of AI, robotic automation, the Internet of Medical Things (IoMT), blockchain, DIY diagnostics, virtual care, mobility in drug delivery and clinical trials, genomics, next-generation therapies, cloud computing, Real-World Evidence (RWE), and data-driven precision medicine are the major technologies driving the life sciences sector. AI technology is being used in diagnoses, treatment planning, patient monitoring, and drug discovery. The IoMT is allowing new business models to emerge and enhancing customer experiences. Pharmaceutical companies are also increasingly using biomarkers in the drug development process to reduce the time taken to bring the product into the market. Biomarkers are biological indicators that are objectively measured and evaluated for biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. The cold and cough preparations market is regulated by authorities such as the Food and Drug Administration in the US. For instance, the Food and Drug Administration (FDA) restricted the use of codeine in children. Codeine is approved to treat pain and cough but this medicine carries serious risks, including slowed or difficult breathing, and can be potentially fatal. This risk is greater in children younger than 12 years but the use of codeine should also be limited in some older children. Single-ingredient codeine is FDA-approved only for use in adults. FDA is also recommending against the use of codeine in breastfeeding mothers due to possible harm to their infants. Major players in the cold and cough preparation market are AstraZeneca, Bayer, Blackmores Limited, Dabur, GlaxoSmithKline, Himalaya Global Holdings, Hyland's, Johnson & Johnson, Novartis and Perrigo Company. North America was the largest region in the cold and cough preparation market in 2022. Middle East is expected to be the fastest-growing region in the global cough and cold preparations market during the forecast period. The regions covered in the global cold and cough preparation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cold and cough preparations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cold and cough preparations market consists of sales of dextromethorphan, guaifenesin, and phenylephrine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cough and cold preparations market is segmented - 1) By Type: Bronchodialators, Anticholinergic, Pulmonary Antihypertensives 2) By Drug Type: Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Other Types 3) By Dosage Type: Oral Syrups, Tablets/Pills, Nasal Drops, Lozenges, Other Dosage Types 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores

Hormonal contraceptive refers to a method of birth control that stops pregnancy using hormones. There are numerous types. Some can be undone, while others are irreversible. Some varieties can also aid in the prevention of STDs. The main types of products in oral contraceptive pills are injectable birth control, emergency contraceptive pills, vaginal rings, and others. Any class of synthetic steroid hormones which inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior lobe of the pituitary gland in the female body is known as oral contraceptive pills or birth control pills. The different hormones include progestin-only, and combined hormones and are used by hospitals, homecare settings, gynecologycenters, clinics, and ambulatory surgical centers. It is distributed through various channels such as drug stores, gynecology or fertility clinics, e-commerce, and others. The hormonal contraceptives market research report is one of a series of new reports from The Business Research Company that provides hormonal contraceptives market statistics, including hormonal contraceptives industry global market size, regional shares, competitors with a hormonal contraceptives market share, detailed hormonal contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal contraceptives industry. This hormonal contraceptive market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hormonal contraceptives market size will grow from $13.47 billion in 2022 to $13.78 billion in 2023 at a compound annual growth rate (CAGR) of 2.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hormonal contraceptives market size is expected to grow to $14.56 billion in 2027 at a CAGR of 1.4%. Increased awareness about the benefits and use of contraceptives is a major factor driving the hormonal contraceptives market. According to the World Health Organization (WHO), 16 million girls worldwide aged 15-19 give birth every year which accounts for approximately 11% of all births globally. To prevent these unplanned births global awareness programs such as It’s your life, it’s your future by the WHO and world contraception day was initiated. The London Summit on Family Planning urged governments, international agencies, and another private sectors to commit to improving access to voluntary family planning. This gave rise to the global partnership, Family Planning 2020 (FP2020). FP2020 has created momentum worldwide on issues such as access to contraceptives, more innovation, and greater accountability in family planning efforts. For example, India will have spent USD$3 billion by 2020 to spread awareness and improve family planning in the country. Moreover, in 2020, according to the United Nations Department of Economic and Social Affairs, about 1.1 billion women aged between 15 and 49 are considered to need family planning. The market for hormonal contraceptive drugs is restrained by the growing use of biologics in place of traditional chemical drugs. Biologics are medicines containing one or more substances derived from a biological source like micro-organisms, animal cells, or human cells. The ability to interact with specific targets puts these medicines above any other drugs, thus hampering the market of chemical-hormonal contraceptive drugs. Companies are innovating to manufacture chewable low-dose oral contraceptives that reduce side effects. The chewable contraceptive initiative was an attempt to reduce side effects while at the same time making it easier for the patients to get into a daily regimen of using this contraceptive. The pill is already being sold as an over-the-counter product. Some of the top companies that produce and sell chewable low-dose oral contraceptives, for instance, are Lupin pharmaceuticals, Walter Chilcott, and Watson pharmaceuticals. Manufacturers in the hormonal contraceptives market should abide by many strict regulations about labeling hormonal contraceptives, and are all supervised by regulatory authorities. For instance, the US FDA has drafted a new set of guidance and labeling recommendations in the hormonal contraceptives market. The main purpose of PLR is to enhance the safety and usage of the particular prescribed drug by providing healthcare providers with clear prescription information (PI). The FDA mandates all hormonal contraceptives to mention the effectiveness of the drug in preventing STDs and any other relevant information regarding the effectiveness of the drug. The FDA considers that communicating information regarding pregnancy rates to the users of these contraceptive drugs is essential for safety and effective usage. Major players in the hormonal contraceptives market are Bayer AG, Merck & Co. Inc., Pfizer, Allergan, Afaxys Inc., TevaPharma Industries Ltd., Agile Therapeutics, HLL Lifecare Limited, Lupin Pharmaceuticals Inc. and Piramal Healthcare Limited. North America was the largest region in the hormonal contraceptives market in 2022. Middle East is expected to be the fastest-growing region in the global hormonal contraceptives market during the forecast period. The regions covered in the global hormonal contraceptives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hormonal contraceptive market includes revenues earned by entities by blocking the release of eggs from the ovaries and thinning the lining of the uterus to prevent pregnancy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global hormonal contraceptives market is segmented - 1) By Product: Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, Other Products 2) By End Users: Hospitals, Homecare Settings, Gynaecology Centers, Clinics, Ambulatory surgical centers 3) By Hormones: Progestin-Only, Combined Hormones 4) By Distribution Channel: Drug Stores, Gynaecology/ Fertility Clinics, E-Commerce, Other Distribution Channels

Oral contraceptive pills refer to a contraceptive tablet that contains hormones that prevent the release of eggs from the ovaries. Oral contraceptives typically contain progestin and oestrogen. Also known as the "birth control pill," it comprises hormones that prevent the emergence of eggs from the ovaries. Most oral contraceptives involve estrogen and progestin.   The oral contraceptive pills market by type into the combination, progestin-only, others; by category into generic, branded; by distribution channel into hospital pharmacy, retail pharmacy, clinics, online channel, public channel and NGO, others. The oral contraceptive pills market research report is one of a series of new reports from The Business Research Company that provides oral contraceptive pills market statistics, including oral contraceptive pills industry global market size, regional shares, competitors with an oral contraceptive pills market share, detailed oral contraceptive pills market segments, market trends and opportunities, and any further data you may need to thrive in the oral contraceptive pills industry. This oral contraceptive pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oral contraceptive pills market grew from $20.13 billion in 2022 to $21.61 billion in 2023 at a compound annual growth rate (CAGR) of 7.35%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oral contraceptive pills market size is expected to grow to $36.09 billion in 2027 at a CAGR of 13.68%. The high incidence of unintended pregnancies is expected to drive the growth of the oral contraceptive pills market over the coming years. Unintended pregnancy is a pregnancy that is always unwanted, such as a pregnancy where no children have been planned. The University of California, San Francisco (UCSF) study shows that the rates of unwanted pregnancy and abortion declined substantially when women received a one-year prescription of oral contraceptives. According to the World Health Organization (WHO), 74 million women living in low-middle-income economies register unplanned pregnancies every year globally. The WHO’s research noticed that 4,794 women had unplanned pregnancies after they had discontinued using contraceptives. Therefore, the need to avoid unintended pregnancies drives the growth of the oral contraceptive pills market. The side effects associated with the use of contraceptive drugs are expected to hinder the growth of the oral contraceptive pills market over the forecast period. An oral contraceptive pill is a hormonal procedure to avoid childbirth. The side effects vary between people and the type of pill consumed. Breast tenderness, headaches, spotting, and nausea are some prominent side effects of oral contraceptive pills. Depo-Provera, an implantable contraceptive, is known to provide the most severe side effects. Research has indicated that Depo-Provera and Depo-SubQ Provera 104 can trigger bone mineral density loss. The U.S. Food and Drug Administration (FDA) attached strict notices to the injection kit saying Depo-Provera and Depo-SubQ Provera 104 could not be used for more than 2 years, attributing to their side effects. The notice also suggests that the use of these medications may increase the risk of osteoporosis and bone disorders later in life. Hence, the side effects associated with the use of contraceptive drugs hamper the growth of the oral contraceptive pill market. Major institutes and companies operating in the oral contraceptive pill sector are focusing on developing innovative solutions for oral contraceptive pills. For instance, in July 2022, HRA Pharma, a France based innovative healthcare company, developed an over the-counter birth control pill called "Opill." HRA Pharma has submitted an application to the Food and Drug Administration in the United States. Opil is a progestin-based contraceptive that helps people access contraception without facing any difficulty. In January 2020, Theramex, a speciality pharmaceutical company for women announced the acquisition of rights to Zoely®, a patented oral contraceptive from Merck &Co for an undisclosed amount. This acquisition aids Theramex in global expansion and adding innovative treatment options for women to its portfolio. Merck & Co. is a US-based multinational pharmaceutical company that has oral contraceptives in its product portfolio. Major players in the contraceptive pills market are Teva Pharmaceutical Industries Ltd., Bayer AG, Syzygy Healthcare, Mankind Pharma Ltd., Pfizer Inc., Piramal Enterprises Ltd., Ferring B.V, Merck & Co. Inc., Johnson & Johnson, and Lupin Pharmaceuticals Inc. North America was the largest region in the oral contraceptive pills market in 2022. The Middle East is expected to be the largest growing region in the forecast period. The regions covered in the contraceptive pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the contraceptive pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The oral contraceptive pills market consists of sales of combined estrogen-progesterone, progesterone-only, and continuous or extended use pill. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global oral contraceptive pills market is segmented - 1) By Type: Combination, Progestin Only, Other Types 2) By Category: Generic, Branded 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel And NGO, Other Distribution Channels

Medical foods refer to a food that has been prepared to be ingested or given orally under the direction of a doctor and designed for the particular dietary. It is designed to help control an existing disease or condition through food. Medical foods are exempt from the labelling requirements for nutrition content claims and health claims. The main types of medical food include pill, powder, and others. The medical food pills refer to a small pellet or a tablet often coated and consumed by swallowing whole or by chewing. Medical food pills are specially formulated to meet nutritional requirements of patients with various medical conditions such as digression, ADHD, and others. They are used in treatment of Alzheimer's Disease, Diabetic Neuropathy, Nutritional Deficiency, ADHD, and others. They are sold through online, retail, and institutional channels. The medical foods market research report is one of a series of new reports from The Business Research Company that provides medical foods market statistics, including medical foods industry global market size, regional shares, competitors with a medical foods market share, detailed medical foods market segments, market trends and opportunities, and any further data you may need to thrive in the medical foods industry. This medical foods market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical foods market size grew from $19.65 billion in 2022 to $21.04 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical foods market size is expected to grow to $27.62 billion in 2027 at a CAGR of 7.0%. The increase in the geriatric population is significantly contributing to the growth of the medical foods market. At the molecular and cellular level, aging is caused by the accumulation of a range of biomolecular damage throughout time. This results in a gradual loss of functional capacity, as well as an increased risk of disease and eventually, death. These changes are not linear or continuous, and they have been only distantly related to a person's chronological age. As people get old, their dependency on certain nutritional foods increases especially medical foods to manage their health from chronic and age-related diseases. For instance, according to the US agency for international public health WHO, the global population aged 60 years and older will increase to 1.4 billion by 2030 from 1 billion in 2020. By 2050, the global population of adults aged 60 and up will have doubled (2.1 billion). Between 2020 and 2050, the number of people aged 80 and more is predicted to triple, reaching 426 million. Therefore, the increase in the geriatric population is expected to propel the growth of the medical foods market. Constant innovations in product development is a key trend gaining popularity in the medical foods market. The companies operating in the medical foods sector are developing innovative products with greater efficacy to cater the demand from customers with specific niche diseases such as metabolic disorders, ADHD, and others. For instance, In February 2020, Galen US Inc., an Ireland-based pharmaceutical company launched PKU EASY Microtabs, a palatable alternative to protein substitutes, and it helps patients above 8 years to manage incurable condition “inherited metabolic disorder, phenylketonuria”. In September 2020, Nestle Health Science, a Swiss-based nutritional science company acquired IM HealthScience (IMH), along with its sister company, Physician's Seal (PS) for an undisclosed amount. With this acquisition, Nestle Health Science aims to strengthen its personalized medicine portfolio and the acquisition fits its mission of empowering healthier lives through nutrition. IM HealthScience (IMH) is a US-based firm that develops products to address overall health and wellness including medical foods. Major players in the medical foods market are Nestle, Mead Johnson & Company LLC, Fresenius Kabi AG, Danone, Primus Pharmaceuticals Inc., Abbott Laboratories, Metagenics Inc., Targeted Medical Pharma Inc., Medtrition Inc., Cerecin Inc., Entera Health Inc., Vaya Pharma Inc., Physician Therapeutics LLC, Alfasigma spA, and MicroBiome Therapeutics LLC. North America was the largest region in the medical foods market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical foods market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medical foods market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The medical foods market consists of sales of oral rehydration products, amino acids, and probiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical foods market is segmented - 1) By Type: Pills, Powder, Other Types 2) By Application: Alzheimers Disease, Diabetic Neuropathy, Nutritional Deficiency, ADHD, Other Applications 3) By Sales Channel: Retail Sales, Online Sales, Institutional Sales

Smart healthcare products are healthcare products that operate on cutting edge technologies such as IoT and AI. These are used to remote monitoring and diagnosis of a patients' health conditions and reduce the cost of the treatment for the user. The main types of smart healthcare products are telemedicine, electronic health records, mHealth, smart pills and syringes and smart RFID cabinets. Telemedicine refers to the electronic transmission of medical information from one location to another to enhance patient health. Smart healthcare products are used for storage and inventory management, monitoring, and treatment and are used in hospitals and home care facilities. The smart healthcare products market research report is one of a series of new reports from The Business Research Company that provides smart healthcare products market statistics, including smart healthcare products industry global market size, regional shares, competitors with a smart healthcare products market share, detailed smart healthcare products market segments, market trends and opportunities, and any further data you may need to thrive in the smart healthcare products industry. This smart healthcare products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global smart healthcare products market size grew from $196.77 billion in 2022 to $222.48 billion in 2023 at a compound annual growth rate (CAGR) of 13.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The smart healthcare products market size is expected to grow to $364.3 billion in 2027 at a CAGR of 13.1%. Increasing healthcare spending is contributing to the growth of the smart healthcare products market. The need for healthcare facilities has immensely increased due to the COVID-19 pandemic. The government's increased emphasis on providing universal healthcare, rising income levels, an aging population, improved healthcare knowledge, higher health insurance penetration, and the increasing burden of non-communicable diseases are the main drivers for healthcare spending growth. Smart healthcare products diagnose and treat an ailment anywhere and anytime. According to the US Centers for Medicare & Medicaid Services (CMS), National Health Expenditure Projections for 2021-2030, the national health spending growth is predicted to climb to 4.6% in 2022 from 4.2% in 2021. Thus, the increasing healthcare spending will drive the market for smart healthcare products. Technological advancement is a key trend in the smart healthcare products market. Artificial intelligence (AI) is improving the efficiency of smart healthcare products. AI has several applications in the health plan, pharmacy benefit managers (PBM), and health system organizations. It will be a crucial engine driving analytics, insights, and decision-making with increasingly interoperable and secure data. In January 2021, ICON.AI, a South Korea-based company that aims to deliver AI-enabled products to every market worldwide, launched the world's first 2-in-one smart healthcare device. The smart healthcare device comprises two primary components: a smart display speaker with built-in Alexa and a detachable health tracker. The smart display speaker can give the weather report, search YouTube, read kindle books, and do a variety of other things. The detachable health tracker detects a medical emergency and promptly notifies the hospital and family members. The critical monitoring features and built-in memory of the smart healthcare device allow transferring health information to smartphones and tablets to share with family and doctors for early diagnosis. In December 2021, Oracle, a US-based computer technology corporation, acquired Cerner Corporation for $28.3 billion. With this acquisition, Oracle's mission now includes the obligation to deliver a new generation of simplified digital tools to busy medical professionals that allow access to data via a hands-free speech interface to secure cloud apps. Cerner Corporation is a US-based that provides various health information technologies, from medical devices to electronic health records to hardware. Major players in the smart healthcare products market are AirStrip Technologies, Samsung Healthcare, Siemens Healthineers AG, Cerner Corporation, McKesson Corporation, Medtronic (Given Imaging Inc), Allscripts Healthcare Solutions, eClinicalWorks, Becton Dickinson and Company, Stanley Healthcare, Terumo Corporation, Next Gen Healthcare, GE Healthcare, Johnson & Johnson, Athenahealth Inc., IBM Corporation and Logi-Tag Systems. North America was the largest region in the smart healthcare products market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the smart healthcare products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the smart healthcare products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The smart healthcare products market consists of sales of wearable activity trackers, wearable biosensors, ECG wearable devices, and other devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global smart healthcare products market is segmented - 1) By Product Type: Telemedicine, Electronic Health Records, mHealth, Smart Pills And Syringes, Smart RFID Cabinets 2) By Application: Storage And Inventory Management, Monitoring, Treatment 3) By End User: Hospitals, Home Care Settings

Smart pills are used to deliver medication and are equipped with electronic sensors that emit signals to be captured by patches or smartphones when they are swallowed. These pills ensure drug regimen compliance and help track medication adherence of patients. The main applications of smart pills are capsule endoscopy, patient monitoring, and drug delivery, patient monitoring involves the repeated or continuous observations or measurements of the patient parameters. These pills are used to target the esophagus, stomach, small intestine, and large intestine to treat diseases such as esophageal diseases, colon diseases, small bowel diseases, and others. Smart pills are used by various end-users such as hospitals, diagnostic centres, and research institutes. The smart pills market research report is one of a series of new reports from The Business Research Company that provides smart pills market statistics, including smart pills industry global market size, regional shares, competitors with a smart pills market share, detailed smart pills market segments, market trends and opportunities, and any further data you may need to thrive in the smart pills industry. This smart pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global smart pills market size will grow from $4.48 billion in 2022 to $4.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global smart pills market size is expected to grow to $7.61 billion in 2027 at a CAGR of 11.2%. The growing preference for non-invasive procedures is driving the smart pills market. The non-invasive procedures are diagnostic and treatment procedures that do not require an incision on the body or removal of tissues for the treatment or diagnosis. Smart pill is a wireless, ingestible capsule that can be easily swallowed and has a wide range of applications in capsule endoscopy, drug delivery, and patient monitoring. For instance, smart pills have key applications in diagnostic imaging such as capsule endoscopy. The capsule endoscopy is a diagnostic procedure in which a smart pill (capsule enclosed micro-camera) is swallowed and images of the esophagus, stomach, and small intestine can be taken as the device pass through your gastrointestinal (GI) tract. Smart pills have revolutionized the diagnosis of gastrointestinal disorders and could replace conventional diagnostic techniques such as endoscopy. Therefore, non-invasive procedures are driving the smart pills market during the period. The high cost of smart pills associated with technological advancement will act as a restraint to the market growth. The utilization of advanced technologies including software up-gradation and innovative systems, and the integration of microchips contribute to the high manufacturing costs of the smart pills. Smart pills are a combination of drug and device technology. A smart pill is an innovative method of drug delivery, which involves the use of sensors and cameras embedded into tiny edible devices. Such medical devices ensure better diagnostics, monitoring, and treatment of life-threatening medical conditions by allowing doctors to monitor their patients’ body functions in real-time. However, the high cost of smart pills led to the limited utilization of products in underdeveloped countries. Thus, the high cost is considered as one of the factors that restrain the growth of the small pills market. Extensive research and development are being carried out on the use of miniature chips such as Addressable Transmitters Operated as Magnetic Spins (ATOMS) which can be used as smart pills. ATOMS are silicon chip devices that use the principle of magnetic resonance imaging (MRI) to determine the location of atoms in a patient’s body using magnetic fields. ATOMS can be used in ingestible smart pills to diagnose and treat diseases from within the body. The devices can be used to monitor a patient’s gastrointestinal tract, blood, or brain. They also could measure factors that indicate the health of a patient such as pH, temperature, pressure, and sugar concentrations, and relay that information to doctors. The devices could even be instructed to release drugs. For instance, scientists at Caltech (California Institute of Technology) have developed a miniature medical chip that can be used as a smart pill. Major players in the smart pills market are Medtronic PLC., Olympus Medical Technology, CapsoVision, Inc., Novartis AG, Proteus Pharmaceuticals, Philips Healthcare, Microchips, Bio-Images Drug Delivery (BDD) Limited, Given Imaging, Inc., and Vitality. North America was the largest region in the smart pills market in 2022. Western Europe was the second-largest region in the global smart pills market. The regions covered in the global smart pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the smart pills market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The smart pills market consists of sales of instruments that are used in applications such as capsule endoscopy, drug delivery, and patient monitoring. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global smart pills market is segmented - 1) By Application: Capsule Endoscopy, Patient Monitoring, Drug Delivery 2) By End User: Hospital, Diagnostic Center, Research Institute 3) By Target Area: Esophagus, Stomach, Small Intestine, Large Intestine 4) By Disease Indication: Esophageal Diseases, Colon Diseases, Small bowel Diseases, and Other Disease Indications

The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant. The main types of gastrointestinal drugs are antacids, antiulcerants, vitamin and minerals, antiobesity, antiemetics and antinauseants and antidiarrhoeals. Antacids are medications that counteract (neutralise) stomach acid to relieve indigestion and heartburn. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global gastrointestinal drugs market size is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%. The change in the gastrointestinal drugs market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The gastrointestinal drugs market is expected to reach $105.51 billion in 2026 at a CAGR of 8.7%. The aging population profile of most countries will contribute to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, will contribute significantly to the growth of the market during the forecast period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This will led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value. Major companies in the gastrointestinal drug industry are investing in making oral capsules of macromolecular drugs for gastrointestinal diseases for making the drug more effective. Macromolecular drugs, such as peptides, proteins, and antibodies, form a new class of drugs which can treat diseases of the gastrointestinal tract, such as inflammatory bowel disease. These macromolecular drugs are usually injected and only a fraction of the administered dose reaches the disease sites in the gastrointestinal tract. Thus, major companies such as Eli Lilly have been increasingly investing in making oral capsules for macromolecular drugs. The company invested $5 million to enter into a collaboration with Entrega to study the oral delivery of complex molecules, such as peptides to combat gastrointestinal diseases. Major companies in the gastrointestinal drugs market include Takeda Pharmaceuticals, Bayer AG, Abbott Laboratories, Otsuka Holdings Co ltd, Johnson & Johnson, Reckitt Benckiser Group plc, Bausch Health Companies Inc., Sanofi S.A, Procter & Gamble and Daiichi Sankyo Company. North America was the largest region in the gastrointestinal drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the gastrointestinal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastrointestinal drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global gastrointestinal drugs market is segmented - 1) By Type: Antacids, Antiulcerants, Vitamin and Minerals, Antiobesity, Antiemetics and Antinauseants, Antidiarrhoeals 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs